康方生物、沛嘉醫療等6家帶"B"字標識的生物科技公司進入港股通
康方生物-B、沛嘉醫療-B、諾誠健華-B、康寧傑瑞製藥-B、亞盛醫藥-B、啓明醫療-B等6家帶"B"字標識的生物科技公司今日起正式納入港股通股票範圍。
12月25日,上交所發佈公告,根據《上海證券交易所滬港通業務實施辦法》有關規定及滬深港3所達成的共識,對符合滬港通下港股通(以下簡稱港股通)納入條件,按照香港聯合交易所《主板上市規則》第18A章節上市,且股份名稱結尾有“B”字標識的生物科技公司股票實施首次納入調整,並自下一港股通交易日起生效。相關調整信息如下:

12月25日,深交所發佈公告,根據《深圳證券交易所深港通業務實施辦法》的有關規定及深滬港交易所達成的共識,按照香港聯合交易所《主板上市規則》第18A章節上市的,股份名稱結尾有“B”字標識的生物科技公司的股票自2020年12月28日起納入港股通股票範圍,相關調整信息如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.